A setback for the Denali-Sanofi partnership
Six years ago, Sanofi gave $125 million and promised over $1 billion in milestone payments to buzzy neuroscience startup Denali Therapeutics to go after a promising new target called RIPK1. That partnership has not gone well. Here's why.
11 Oct 13:39 · STAT